Chemomab Therapeutics Statistics
Total Valuation
CMMB has a market cap or net worth of $9.66 million. The enterprise value is -$9.81 million.
| Market Cap | 9.66M |
| Enterprise Value | -9.81M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CMMB has 14.20 million shares outstanding.
| Shares Outstanding | 14.20M |
| Owned by Insiders (%) | 14.99% |
| Owned by Institutions (%) | 24.96% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 13.00 |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.57 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.32, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.32 |
| Quick Ratio | 4.32 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -114.00% and return on invested capital (ROIC) is -146.41%.
| Return on Equity (ROE) | -114.00% |
| Return on Assets (ROA) | -88.50% |
| Return on Capital (ROIC) | -146.41% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.21M |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.52% in the last 52 weeks. The beta is -0.04, so CMMB's price volatility has been lower than the market average.
| Beta (1Y) | -0.04 |
| 52-Week Price Change | -59.52% |
| 50-Day Moving Average | 0.73 |
| 200-Day Moving Average | 0.81 |
| Relative Strength Index (RSI) | 43.66 |
| Average Volume (30 Days) | 227,661 |
Short Selling Information
| Short Interest | 221,869 |
| Short Previous Month | 194,154 |
| Short % of Shares Out | 1.65% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.14 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -25.46M |
| Pretax Income | -24.22M |
| Net Income | -24.22M |
| EBITDA | -24.15M |
| EBIT | -24.22M |
| Earnings Per Share (EPS) | -$2.06 |
Balance Sheet
The company has $19.86 million in cash and $392,000 in debt, giving a net cash position of $19.47 million or $1.37 per share.
| Cash & Cash Equivalents | 19.86M |
| Total Debt | 392,000 |
| Net Cash | 19.47M |
| Net Cash Per Share | $1.37 |
| Equity / Book Value | 17.00M |
| Book Value Per Share | 1.20 |
| Working Capital | 16.06M |
Cash Flow
In the last 12 months, operating cash flow was -$23.61 million and capital expenditures -$3,000, giving a free cash flow of -$23.61 million.
| Operating Cash Flow | -23.61M |
| Capital Expenditures | -3,000 |
| Free Cash Flow | -23.61M |
| FCF Per Share | -$2.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CMMB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.26% |
| Shareholder Yield | -3.26% |
| Earnings Yield | -250.76% |
| FCF Yield | -244.47% |
Analyst Forecast
The average price target for CMMB is $7.00, which is 929.41% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.00 |
| Price Target Difference | 929.41% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -50.50% |
Stock Splits
The last stock split was on March 17, 2021. It was a reverse split with a ratio of 1:16.
| Last Split Date | Mar 17, 2021 |
| Split Type | Reverse |
| Split Ratio | 1:16 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |